91ÖĆƬł§

Published on Market Research Reports® Inc. ()

Home > Global Transarterial Chemoembolization (TACE) Market Research Report 2023

Global Transarterial Chemoembolization (TACE) Market Research Report 2023

Publication ID: 
PB510235817
Publication Date: 
October 17, 2023
Pages: 
96
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 2,900.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Medical Devices [2]
Pharma & Healthcare [3]
Description: 

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
The global Transarterial Chemoembolization (TACE) market is projected to reach US$ 18970 million in 2029, increasing from US$ 10930 million in 2022, with the CAGR of 8.3% during the period of 2023 to 2029.
The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.
Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.
The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.
Some key factors driving the global TACE market include:
Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.
Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.
Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.
Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.
The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Transarterial Chemoembolization (TACE) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth
Segment by Type
Chemotherapeutic Agents
Radio Therapeutic Agents
Drug-eluting Particles
Others
Segment by Application
Hospitals
Clinics
Cancer Research Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Transarterial Chemoembolization (TACE) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transarterial Chemoembolization (TACE) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapeutic Agents
1.2.3 Radio Therapeutic Agents
1.2.4 Drug-eluting Particles
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transarterial Chemoembolization (TACE) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Research Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transarterial Chemoembolization (TACE) Market Perspective (2018-2029)
2.2 Transarterial Chemoembolization (TACE) Growth Trends by Region
2.2.1 Global Transarterial Chemoembolization (TACE) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Transarterial Chemoembolization (TACE) Historic Market Size by Region (2018-2023)
2.2.3 Transarterial Chemoembolization (TACE) Forecasted Market Size by Region (2024-2029)
2.3 Transarterial Chemoembolization (TACE) Market Dynamics
2.3.1 Transarterial Chemoembolization (TACE) Industry Trends
2.3.2 Transarterial Chemoembolization (TACE) Market Drivers
2.3.3 Transarterial Chemoembolization (TACE) Market Challenges
2.3.4 Transarterial Chemoembolization (TACE) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transarterial Chemoembolization (TACE) Players by Revenue
3.1.1 Global Top Transarterial Chemoembolization (TACE) Players by Revenue (2018-2023)
3.1.2 Global Transarterial Chemoembolization (TACE) Revenue Market Share by Players (2018-2023)
3.2 Global Transarterial Chemoembolization (TACE) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transarterial Chemoembolization (TACE) Revenue
3.4 Global Transarterial Chemoembolization (TACE) Market Concentration Ratio
3.4.1 Global Transarterial Chemoembolization (TACE) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transarterial Chemoembolization (TACE) Revenue in 2022
3.5 Transarterial Chemoembolization (TACE) Key Players Head office and Area Served
3.6 Key Players Transarterial Chemoembolization (TACE) Product Solution and Service
3.7 Date of Enter into Transarterial Chemoembolization (TACE) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transarterial Chemoembolization (TACE) Breakdown Data by Type
4.1 Global Transarterial Chemoembolization (TACE) Historic Market Size by Type (2018-2023)
4.2 Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Type (2024-2029)
5 Transarterial Chemoembolization (TACE) Breakdown Data by Application
5.1 Global Transarterial Chemoembolization (TACE) Historic Market Size by Application (2018-2023)
5.2 Global Transarterial Chemoembolization (TACE) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Transarterial Chemoembolization (TACE) Market Size (2018-2029)
6.2 North America Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Transarterial Chemoembolization (TACE) Market Size by Country (2018-2023)
6.4 North America Transarterial Chemoembolization (TACE) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transarterial Chemoembolization (TACE) Market Size (2018-2029)
7.2 Europe Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Transarterial Chemoembolization (TACE) Market Size by Country (2018-2023)
7.4 Europe Transarterial Chemoembolization (TACE) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size (2018-2029)
8.2 Asia-Pacific Transarterial Chemoembolization (TACE) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2018-2023)
8.4 Asia-Pacific Transarterial Chemoembolization (TACE) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transarterial Chemoembolization (TACE) Market Size (2018-2029)
9.2 Latin America Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2018-2023)
9.4 Latin America Transarterial Chemoembolization (TACE) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size (2018-2029)
10.2 Middle East & Africa Transarterial Chemoembolization (TACE) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2018-2023)
10.4 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Questex
11.1.1 Questex Company Detail
11.1.2 Questex Business Overview
11.1.3 Questex Transarterial Chemoembolization (TACE) Introduction
11.1.4 Questex Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.1.5 Questex Recent Development
11.2 Siemens Healthcare GmbH
11.2.1 Siemens Healthcare GmbH Company Detail
11.2.2 Siemens Healthcare GmbH Business Overview
11.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Introduction
11.2.4 Siemens Healthcare GmbH Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.2.5 Siemens Healthcare GmbH Recent Development
11.3 Bellicum Pharmaceuticals Inc.
11.3.1 Bellicum Pharmaceuticals Inc. Company Detail
11.3.2 Bellicum Pharmaceuticals Inc. Business Overview
11.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Introduction
11.3.4 Bellicum Pharmaceuticals Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.3.5 Bellicum Pharmaceuticals Inc. Recent Development
11.4 Boston Scientific
11.4.1 Boston Scientific Company Detail
11.4.2 Boston Scientific Business Overview
11.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Introduction
11.4.4 Boston Scientific Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.4.5 Boston Scientific Recent Development
11.5 Cook Group
11.5.1 Cook Group Company Detail
11.5.2 Cook Group Business Overview
11.5.3 Cook Group Transarterial Chemoembolization (TACE) Introduction
11.5.4 Cook Group Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.5.5 Cook Group Recent Development
11.6 Hikma Pharmaceuticals
11.6.1 Hikma Pharmaceuticals Company Detail
11.6.2 Hikma Pharmaceuticals Business Overview
11.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Introduction
11.6.4 Hikma Pharmaceuticals Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.6.5 Hikma Pharmaceuticals Recent Development
11.7 Nippon Kayaku
11.7.1 Nippon Kayaku Company Detail
11.7.2 Nippon Kayaku Business Overview
11.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Introduction
11.7.4 Nippon Kayaku Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.7.5 Nippon Kayaku Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Transarterial Chemoembolization (TACE) Introduction
11.8.4 Novartis AG Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.8.5 Novartis AG Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Detail
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Introduction
11.9.4 Pfizer Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.9.5 Pfizer Inc. Recent Development
11.10 Spectrum Pharmaceutical
11.10.1 Spectrum Pharmaceutical Company Detail
11.10.2 Spectrum Pharmaceutical Business Overview
11.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Introduction
11.10.4 Spectrum Pharmaceutical Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.10.5 Spectrum Pharmaceutical Recent Development
11.11 Roche Holding AG
11.11.1 Roche Holding AG Company Detail
11.11.2 Roche Holding AG Business Overview
11.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Introduction
11.11.4 Roche Holding AG Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.11.5 Roche Holding AG Recent Development
11.12 Celgene
11.12.1 Celgene Company Detail
11.12.2 Celgene Business Overview
11.12.3 Celgene Transarterial Chemoembolization (TACE) Introduction
11.12.4 Celgene Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.12.5 Celgene Recent Development
11.13 Bayer AG
11.13.1 Bayer AG Company Detail
11.13.2 Bayer AG Business Overview
11.13.3 Bayer AG Transarterial Chemoembolization (TACE) Introduction
11.13.4 Bayer AG Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.13.5 Bayer AG Recent Development
11.14 Merck & Co., Inc.
11.14.1 Merck & Co., Inc. Company Detail
11.14.2 Merck & Co., Inc. Business Overview
11.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Introduction
11.14.4 Merck & Co., Inc. Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.14.5 Merck & Co., Inc. Recent Development
11.15 SingHealth
11.15.1 SingHealth Company Detail
11.15.2 SingHealth Business Overview
11.15.3 SingHealth Transarterial Chemoembolization (TACE) Introduction
11.15.4 SingHealth Revenue in Transarterial Chemoembolization (TACE) Business (2018-2023)
11.15.5 SingHealth Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned: 

Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-transarterial-chemoembolization-tace-market-research-report-2023

Links
[1] /countries/global[2] /medical-devices[3] /pharma-healthcare